Home › All Companies › TXG › Annual Report

10x Genomics, Inc. (TXG) — Annual Report

AI-Powered SEC Filing Analysis

← All TXG filings
Latest Annual Report Filed: 2026-02-13

Key Insights

  • 10x Genomics reported strong revenue growth of 25% year-over-year in 2025, driven by continued demand for its product and service offerings.
  • The company's gross margin improved by 2 percentage points in 2025, indicating improved operational efficiency and cost control.
  • 10x Genomics provided a positive outlook for 2026, forecasting 18-22% revenue growth and stable profitability, though the acquisition of Scale BioScience introduces some uncertainty.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for 10x Genomics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.